An Open-Label Positron Emission Tomography (PET) Study to Demonstrate Receptor Occupancy, Safety, Tolerability and Pharmacokinetics of ITI-007 in Stable Schizophrenia Patients

Trial Profile

An Open-Label Positron Emission Tomography (PET) Study to Demonstrate Receptor Occupancy, Safety, Tolerability and Pharmacokinetics of ITI-007 in Stable Schizophrenia Patients

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Mar 2017

At a glance

  • Drugs Lumateperone (Primary)
  • Indications Schizophrenia
  • Focus Pharmacodynamics
  • Sponsors Intra-Cellular Therapies
  • Most Recent Events

    • 06 Apr 2016 Results published in the Media Release an Intra-Cellular Therapies media release.
    • 06 Apr 2016 Results presented at the 54th annual meeting of the American College of Neuropsychopharmacology (ACNP), according to an Intra-Cellular Therapies media release.
    • 06 Apr 2016 Data presented at the 5th Biennial Schizophrenia International Research Society (SIRS) Conference 2016, according to an Intra-Cellular Therapies media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top